See more : IXICO plc (PHYOF) Income Statement Analysis – Financial Results
Complete financial analysis of Ocugen, Inc. (OCGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ocugen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Morepen Laboratories Limited (MOREPENLAB.BO) Income Statement Analysis – Financial Results
- BlackRock MuniAssets Fund, Inc. (MUA) Income Statement Analysis – Financial Results
- CEAT Limited (CEATLTD.BO) Income Statement Analysis – Financial Results
- Konami Group Corporation (KONMY) Income Statement Analysis – Financial Results
- LG Innotek Co., Ltd. (011070.KS) Income Statement Analysis – Financial Results
Ocugen, Inc. (OCGN)
About Ocugen, Inc.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.04M | 2.49M | 0.00 | 42.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 26.00K |
| Cost of Revenue | 704.00K | 1.07M | 589.00K | 6.35K | 60.61K | 49.62K | 1.53M | 1.67M | 1.61M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.33M | 1.42M | -589.00K | 36.27K | -60.61K | -49.62K | -1.53M | -1.67M | -1.61M | 0.00 | 8.00K | 26.00K |
| Gross Profit Ratio | 88.34% | 56.87% | 0.00% | 85.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 39.57M | 49.76M | 35.11M | 6.35M | 8.09M | 15.63M | 15.57M | 21.58M | 23.24M | 25.86M | 11.95M | 11.94M |
| General & Administrative | 31.99M | 35.11M | 22.92M | 7.97M | 6.08M | 10.20M | 9.38M | 8.53M | 8.27M | 6.75M | 4.85M | 3.05M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.99M | 35.11M | 22.92M | 7.97M | 6.08M | 10.20M | 9.38M | 8.53M | 8.27M | 6.75M | 4.85M | 3.05M |
| Other Expenses | 0.00 | 3.52M | -310.00K | 182.66K | -784.87K | 1.43M | -116.00K | -248.00K | -72.00K | 13.00K | -52.00K | -30.00K |
| Operating Expenses | 71.57M | 84.87M | 58.03M | 14.33M | 14.16M | 25.84M | 24.95M | 30.11M | 31.51M | 32.60M | 16.79M | 14.99M |
| Cost & Expenses | 71.57M | 84.87M | 58.03M | 14.33M | 14.16M | 25.84M | 24.95M | 30.11M | 31.51M | 32.60M | 16.79M | 14.99M |
| Interest Income | 0.00 | 1.40M | 0.00 | 1.07K | 1.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 79.00K | 720.96K | 1.77M | 163.00K | 134.00K | -60.00K | -133.00K | -151.00K | 0.00 | 798.00K |
| Depreciation & Amortization | 704.00K | 480.00K | 589.00K | 102.11K | 60.61K | 49.62K | 1.53M | 1.67M | 1.61M | 726.00K | 566.00K | 638.00K |
| EBITDA | -64.83M | -88.59M | -58.03M | -21.00M | -18.41M | -14.42M | -24.88M | -11.38M | -30.28M | -21.92M | -16.22M | -14.33M |
| EBITDA Ratio | -1,074.01% | -3,411.09% | 0.00% | -33,085.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -91,800.00% | -50,734.62% |
| Operating Income | -65.53M | -84.87M | -58.03M | -21.28M | -14.16M | -30.11M | -24.95M | -30.31M | -31.82M | -32.66M | -16.85M | -14.97M |
| Operating Income Ratio | -1,085.67% | -3,411.09% | 0.00% | -49,940.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -210,562.50% | -57,569.23% |
| Total Other Income/Expenses | 2.45M | 2.27M | -389.00K | -536.95K | -6.08M | 11.89M | -1.46M | 14.10M | -205.00K | 9.87M | -8.87M | -1.97M |
| Income Before Tax | -63.08M | -81.35M | -58.42M | -21.82M | -20.24M | -8.64M | -26.41M | -16.21M | -32.02M | -22.79M | -25.71M | -16.94M |
| Income Before Tax Ratio | -1,045.03% | -3,269.73% | 0.00% | -51,201.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -321,400.00% | -65,134.62% |
| Income Tax Expense | 0.00 | -4.00M | -52.00K | 801.52K | 982.96K | -15.76M | -186.00K | -15.82M | -1.17M | -10.52M | 8.88M | 1.94M |
| Net Income | -63.08M | -77.83M | -58.37M | -22.62M | -21.23M | -8.64M | -26.41M | -16.21M | -32.02M | -22.79M | -25.71M | -16.94M |
| Net Income Ratio | -1,045.03% | -3,128.38% | 0.00% | -53,081.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -321,400.00% | -65,134.62% |
| EPS | -0.26 | -0.36 | -0.30 | -0.20 | -1.53 | -13.98 | -69.91 | -68.21 | -145.22 | -891.47 | -120.93 | -79.65 |
| EPS Diluted | -0.26 | -0.36 | -0.30 | -0.20 | -1.53 | -13.98 | -69.91 | -67.58 | -145.22 | -891.47 | -120.93 | -79.65 |
| Weighted Avg Shares Out | 244.33M | 214.60M | 195.01M | 112.24M | 13.89M | 618.18K | 377.83K | 237.62K | 220.52K | 25.57K | 212.62K | 212.62K |
| Weighted Avg Shares Out (Dil) | 244.33M | 214.60M | 195.01M | 112.24M | 13.89M | 618.18K | 377.84K | 239.82K | 220.52K | 25.57K | 212.62K | 212.62K |
Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading
SAN FRANCISCO , Aug. 20, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Ocugen, Inc. investors that the firm is investigating potential legal claims relating to an earnings restatement and possible substantial insider trading by key executives and company directors....
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial OCU410 preliminary safety and efficacy data expected later this year Expanded access program approved for OCU400 $32.6 million net cash from...
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
MALVERN, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it has received notification from...
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
MALVERN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the closing of its previously announced underwritten public offering of...
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the pricing of its underwritten public offering of 30,434,783 shares...
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it has commenced an underwritten public offering (the “offering”)...
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference...
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced...
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
CRISPR Therapeutics could ride the wave of its first approval to deliver solid performance over the long run. Despite decent clinical progress, Ocugen remains a high-risk play that has yet to show its long-run potential.
3 Penny Stocks That Could Turn $10K Into $100K in 3 Years
Investing in penny stocks can be a gateway to high financial gains, particularly when identifying high-potential opportunities. Here, the spotlight is on three high-potential penny stocks that possess the potential to transform a $10,000 investment into $100,000 within three years.
Source: https://incomestatements.info
Category: Stock Reports